Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Clovis Oncology, Inc. - Common Stock (NQ: CLVS )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Clovis Oncology, Inc. - Common Stock

< Previous 1 2 Next >
Analysts Holding As Pfizer Waits On Two Phase 3 Studies
Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value. 
Via MarketBeat
Topics Bankruptcy
Exposures Financial Legal
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat
From Clovis
Via Business Wire
Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies
Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound, and... 
Via FinancialNewsMedia
Exposures COVID-19
Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress
From Clovis
Via Business Wire
TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations
From Clovis
Via Business Wire
Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
From Clovis Oncology, Inc.
Via Business Wire
CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD Status
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
From Clovis Oncology, Inc.
Via Business Wire
HER2-Targeted Therapies Introduced Early in Breast Cancer Treatment Offering Hope for Patients
Palm Beach, FL – May 4, 2022 – FinancialNewsMedia.com News Commentary – Globally, the R&D on breast cancer in all its forms has been steadily growing at a significant pace over the last several years... 
Via FinancialNewsMedia
Exposures COVID-19
Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting
From Clovis Oncology, Inc.
Via Business Wire
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer... 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4
From Clovis Oncology, Inc.
Via Business Wire
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically... 
Via FinancialNewsMedia
Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit
From Clovis Oncology, Inc.
Via Business Wire
Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027
Palm Beach, FL – November 3, 2021 – FinancialNewsMedia.com News Commentary – The metastatic cancer treatment systems market is observing high demand attributed to its increasing application in breast,... 
Via FinancialNewsMedia
Clovis Oncology Announces Third Quarter 2021 Operating Results
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3
From Clovis Oncology, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.